Li Xu

9.0k total citations · 3 hit papers
195 papers, 5.2k citations indexed

About

Li Xu is a scholar working on Hepatology, Surgery and Cancer Research. According to data from OpenAlex, Li Xu has authored 195 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 82 papers in Hepatology, 48 papers in Surgery and 46 papers in Cancer Research. Recurrent topics in Li Xu's work include Hepatocellular Carcinoma Treatment and Prognosis (80 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (35 papers) and Liver Disease Diagnosis and Treatment (26 papers). Li Xu is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (80 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (35 papers) and Liver Disease Diagnosis and Treatment (26 papers). Li Xu collaborates with scholars based in China, United States and Hong Kong. Li Xu's co-authors include Yaojun Zhang, Minshan Chen, Rong Guo, Ming Shi, Zhenwei Peng, Min-Shan Chen, Zhongguo Zhou, Xiao-Jun Lin, Wan Yee Lau and Wei Wei and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of the American Chemical Society and Journal of Clinical Investigation.

In The Last Decade

Li Xu

184 papers receiving 5.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion

2019 372 citations Minke He, QiJiong Li et al. profile →
Radiofrequency Ablation With or Without Transcatheter Arterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Prospective Randomized Trial

2012 369 citations Zhenwei Peng, Yaojun Zhang et al. Journal of Clinical Oncology profile →
Lenvatinib, toripalimab plus hepatic arterial infusion chemotherapy in patients with high-risk advanced hepatocellular carcinoma: A biomolecular exploratory, phase II trial

2022 119 citations ZhiCheng Lai, Minke He et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Li Xu China	39	2.6k	1.3k	1.2k	1.1k	1000	195	5.2k
Minshan Chen China	35	3.1k 1.2×	1.3k 1.0×	1.4k 1.2×	949 0.8×	889 0.9×	190	5.1k
Zhenggang Ren China	44	2.9k 1.1×	2.1k 1.6×	1.3k 1.1×	1.0k 0.9×	1.5k 1.5×	174	5.9k
Su Jong Yu South Korea	38	3.2k 1.3×	1.2k 0.9×	2.9k 2.4×	941 0.8×	1.1k 1.1×	280	6.2k
Jian‐Hong Zhong China	33	2.5k 1.0×	987 0.8×	1.5k 1.3×	1.0k 0.9×	706 0.7×	178	4.3k
Keizo Dono Japan	40	2.0k 0.8×	1.9k 1.5×	1.1k 0.9×	1.9k 1.6×	1.7k 1.7×	246	5.7k
Satoru Imura Japan	33	1.2k 0.5×	1.2k 1.0×	733 0.6×	2.2k 1.9×	1.1k 1.1×	255	4.6k
Jens U. Marquardt Germany	40	1.5k 0.6×	1.1k 0.9×	1.0k 0.9×	892 0.8×	2.1k 2.1×	185	4.7k
Yuji Morine Japan	34	1.2k 0.5×	1.3k 1.0×	749 0.6×	1.7k 1.5×	1.2k 1.2×	272	4.4k
Osamu Nakashima Japan	46	4.6k 1.8×	1.7k 1.3×	2.9k 2.4×	2.2k 1.9×	976 1.0×	204	7.5k
Tohru Utsunomiya Japan	37	1.3k 0.5×	1.7k 1.3×	880 0.7×	978 0.9×	1.5k 1.5×	166	4.3k

Countries citing papers authored by Li Xu

Since Specialization

Citations

This map shows the geographic impact of Li Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Li Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Li Xu more than expected).

Fields of papers citing papers by Li Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Li Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Li Xu. The network helps show where Li Xu may publish in the future.

Co-authorship network of co-authors of Li Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Li Xu. A scholar is included among the top collaborators of Li Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Li Xu. Li Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cao, Hui, Youjuan Wang, Shiyi Liao, et al.. (2025). Ultrabright difuranfluoreno-dithiophen polymers for enhanced afterglow imaging of atherosclerotic plaques. Science Advances. 11(13). eads4646–eads4646. 1 indexed citations

Xu, Li, et al.. (2024). Intravenous versus oral tranexamic acid in elderly transforaminal lumbar interbody fusion patients: A prospective cohort study. Clinical Neurology and Neurosurgery. 246. 108607–108607.

Ji, Peng, et al.. (2024). Enhanced breast cancer therapy using multifunctional lipid-coated nanoparticles combining curcumin chemotherapy and nitric oxide gas delivery. Scientific Reports. 14(1). 18107–18107. 7 indexed citations

Wang, Xin, Yizhen Fu, Weijie Wu, et al.. (2024). YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment. Molecular Cancer. 23(1). 186–186. 17 indexed citations

He, Minke, ZhiCheng Lai, QiJiong Li, et al.. (2023). Hepatic arterial infusion chemotherapy for patients with hepatocellular carcinoma: Applicability in Western countries. Current Opinion in Pharmacology. 70. 102362–102362. 8 indexed citations

Lai, ZhiCheng, JingXian Shen, QiJiong Li, et al.. (2023). Lenvatinib, Toripalimab plus FOLFOX Chemotherapy in Hepatocellular Carcinoma Patients with Extrahepatic Metastasis: A Biomolecular Exploratory, Phase II Trial (LTSC). Clinical Cancer Research. 29(24). 5104–5115. 17 indexed citations

Wang, Jiongliang, Juncheng Wang, Yangxun Pan, et al.. (2023). Systemic Inflammation Score Using Pretherapeutic Inflammatory Markers to Predict Prognosis for Hepatocellular Carcinoma Patients After Hepatic Arterial Infusion Chemotherapy. Journal of Hepatocellular Carcinoma. Volume 10. 2133–2145. 3 indexed citations

Jiang, Wei, Fan Zhu, Li Xu, et al.. (2023). CHI3L1 signaling impairs hippocampal neurogenesis and cognitive function in autoimmune-mediated neuroinflammation. Science Advances. 9(39). eadg8148–eadg8148. 27 indexed citations

Wang, Yuge, Li Xu, Yilong Shan, et al.. (2023). Decreased kynurenine in cerebrospinal fluid and potential role in neuromyelitis optica spectrum disorder. Journal of Neurochemistry. 165(2). 259–267.

10.

Fu, Yizhen, Zili Hu, Yangxun Pan, et al.. (2022). Inflammation-Based Scores Predict Responses to PD-1 Inhibitor Treatment in Intrahepatic Cholangiocarcinoma. Journal of Inflammation Research. Volume 15. 5721–5731. 20 indexed citations

11.

Chen, Dong‐Ping, Shi‐Xun Lu, Jinbin Chen, et al.. (2022). PIM2 Expression Induced by Proinflammatory Macrophages Suppresses Immunotherapy Efficacy in Hepatocellular Carcinoma. Cancer Research. 82(18). 3307–3320. 12 indexed citations

12.

Hu, Zili, Juncheng Wang, Li Xu, et al.. (2022). Tenofovir vs. Entecavir on Outcomes of Hepatitis B Virus-Related Hepatocellular Carcinoma after Radiofrequency Ablation. Viruses. 14(4). 656–656. 10 indexed citations

13.

Luo, Wenjing, Huiming Xu, Li Xu, et al.. (2022). Remyelination in neuromyelitis optica spectrum disorder is promoted by edaravone through mTORC1 signaling activation. Glia. 71(2). 284–304. 18 indexed citations

14.

Choi, Seongjin, et al.. (2021). Multi-layer analysis of quantitative 7 T magnetic resonance imaging in the cortex of multiple sclerosis patients reveals pathology associated with disability. Multiple Sclerosis Journal. 27(13). 2040–2051. 9 indexed citations

15.

Sun, Wen, Shichao Li, Li Xu, et al.. (2020). High FLT3 Levels May Predict Sorafenib Benefit in Hepatocellular Carcinoma. Clinical Cancer Research. 26(16). 4302–4312. 16 indexed citations

16.

Zhou, Zhongguo, Jinbin Chen, Rongxin Zhang, et al.. (2020). Tescalcin is an unfavorable prognosis factor that regulats cell proliferation and survival in hepatocellular carcinoma patients. Cancer Communications. 40(8). 355–369. 12 indexed citations

17.

Pan, Yangxun, Jinbin Chen, Dandan Hu, et al.. (2020). Single versus multiple port laparoscopic left lateral sectionectomy for hepatocellular carcinoma: A retrospective comparative study. International Journal of Surgery. 77. 15–21. 2 indexed citations

18.

Wu, Chong, Jie Lin, Yulan Weng, et al.. (2020). Myeloid signature reveals immune contexture and predicts the prognosis of hepatocellular carcinoma. Journal of Clinical Investigation. 130(9). 4679–4693. 51 indexed citations

19.

Xu, Jing, Jing Liang, Ya-Ming Meng, et al.. (2017). Vascular CXCR4 Expression Promotes Vessel Sprouting and Sensitivity to Sorafenib Treatment in Hepatocellular Carcinoma. Clinical Cancer Research. 23(15). 4482–4492. 42 indexed citations

20.

Peng, Zhenwei, Yaojun Zhang, Min-Shan Chen, et al.. (2012). Radiofrequency Ablation With or Without Transcatheter Arterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Prospective Randomized Trial. Journal of Clinical Oncology. 31(4). 426–432. 369 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact